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PI3Kns of high risk Human papillomavirus (HPV) have been associated with a
differential threat for cervical cancer development. In this work, the effect of HPV18 E6 isolates in Akt/PKB
and Mitogen-associated protein kinase (MAPKs) signaling pathways and its implication in cell proliferation
were analyzed. E6 from HPV types 16 and 18 are able to bind and promote degradation of Human disc large
(hDlg). Our results show that E6 variants differentially modulate hDlg degradation, rebounding in levels of
activated PTEN and PKB. HPV18 E6 variants are also able to upregulate phospho-PI3K protein, strongly
correlating with activated MAPKs and cell proliferation. Data was supported by the effect of E6 silencing in
HPV18-containing HeLa cells, as well as hDlg silencing in the tested cells. Results suggest that HPV18 intra-
type variations may derive in differential abilities to activate cell-signaling pathways such as Akt/PKB and
MAPKs, directly involved in cell survival and proliferation.
© 2008 Elsevier Inc. All rights reserved.IntroductionHigh-risk Human Papilloma Virus (HPV) is the major etiological
agent of cervical cancer. It is well known that only a small number of
cervical lesions infected with high risk HPVs evolve to higher grade
lesions or cervical cancer (Bosch et al., 2002; zur Hausen, 2002). HPV
type and persistence of infection are critical factors involved in cervical
cancer progression. Intra-type variation could be an important factor
inﬂuencing cervical cancer development (Dalstein et al., 2003;
Hildesheim et al., 2001; Lizano et al., 1997). It has been shown that
variations in E6 viral oncogene could affect HPV biological behavior
(Kammer et al., 2002; Stoppler et al., 1996). Different E6 splicing
patterns within HPV18 variants have been proposed to affect the ﬁnal
cellular concentration of full-length E6 (De la Cruz et al., 2005).
E6 and E7 are the main viral proteins involved in human epithelial
cell immortalization and transformation (Mantovani and Banks,
2001). A rather large number of cellular targets of E6 and E7
oncoproteins have been identiﬁed and several of these interactions
are assumed to participate in deregulation of cellular processes, such
as cell proliferation and apoptosis (Malanchi et al., 2004; Motoyama et
al., 2004). Nevertheless, some cellular pathways that HPV oncogenes
affect are not well dissected. In vitro assays as well as results obtained
through cervical cancer cell line analysis, have demonstrated that E6reras-Paredes),
l rights reserved.proteins from high risk HPV, bind to a PDZ-2 domain of hDlg
(Postsynaptic synaptic density–Discs large–Zona occludens) (Lee
et al., 1997; Thomas et al., 2001; Zhang et al., 2007) promoting its
degradation via the ubiquitin proteosome pathway (Grm and Banks,
2004; Mantovani et al., 2001b; Massimi et al., 2004).
hDlg, is a member of the membrane-associated guanylate kinase
(MAGUK) family of proteins, involved in the inhibition of cell cycle
progression. It has been reported that cellular hDlg levels are greatly
reduced or absent in high grade cervical neoplasia, aswell as in cervical
squamous cell carcinomas, (Watson et al., 2002). hDlg expression is
also diminished in transformed cell types (Lin et al., 2004).
It has been shown that variousmembers of theMAGUK family bind
and modulate PTEN (Phosphatase and Tensin Homolog) activity
through formation of multicomponent protein complexes (Adey et
al., 2000; Thomas et al., 2001; Valiente et al., 2005). hDlg is also able to
bind PTEN tumor suppressor protein, through its PDZ domains (Adey
et al., 2000).
PTEN phosphatase is a negative regulator of the Serine/threonine
kinase/Protein kinase B (Akt/PKB) survival pathway (Sansal and Sellers,
2004). Activation of this pathway in cervical cancer has been explained
by PTEN levels reduction (Tak-Hong et al., 2004). Nevertheless,
diminished PTEN expression has only been found in aminor proportion
of invasive cervical cancers (Lee et al., 2006; Mei et al., 2005). PTEN
mutations are common inmany human cancers (Haluska et al., 2006; Li
et al.,1997;Mei et al., 2005; Pedrero et al., 2005; Tashiro et al.,1997), but
are infrequent in cervical cancer (Harimaet al., 2001;Kurose et al., 2000;
Su et al., 2000; Yaginuma et al., 2000). Reduction of PTEN expression in
Fig. 1. (a) PTEN promoter is unmethylated in cervical cancer cell lines. Methylation status of PTEN promoter was determined through MSP in MCF-7, Caski, SiHa, and HeLa, cell lines.
Bisulﬁte-modiﬁed DNA was PCR ampliﬁed with speciﬁc primers: Methylated primers (M) or unmethylated primers (U). DNA extracted from lymphocytes, untreated and in vitro
methylated, was used as control. A PCR ampliﬁcation product was obtained only with unmethylated primers in tested cervical cell lines, revealing the unmethylated status of PTEN
promoter. Lymphocyte PTEN promoter is naturally found methylated; the proportion of methylated DNA increased in DNA methylated in vitro. (b) pPTEN is diminished in cell lines
transfected with HPV18 E6 variants. Western blot analysis of PTEN protein levels was done in MCF-7 extracts with E-, AsAi-, and Af-HPV18 E6 and pcDNA vector alone. Analysis was
performed with Anti-PTEN antibody (Upper panel); phosphorylated PTEN (pPTEN) levels were evaluated with antibodies recognizing 388 and 396 tyr (Middle panel). Lower panel:
anti-Actin antibody, as protein loading control.
Fig. 2. HPV18 E6 variants promote hDlg degradation. Western blot analysis with anti-
hDlg antibody shows different amounts of hDlg total protein in MCF7 cells (a), or C33
cells (b) transfected with the E6 isolates (Af, E, or AsAi). Anti-actin antibody was used as
protein-loading control.
79A. Contreras-Paredes et al. / Virology 383 (2009) 78–85cervical neoplasia has been explained by promoter methylation-
involved epigenetic mechanisms (Cheung et al., 2004).
Diverse elements in the Akt/PKB pathway are critical in cell
survival and proliferation (Lawlor and Alessi, 2001). It is well known
that Phosphatidyl Inositol 3-kinase (PI3K) is a positive regulator of the
Akt/PKB pathway, which in turn induces the expression of transcrip-
tional factors involved in proliferative and antiapoptotic signals
(Downward, 2004). The PI3K-triggered process is negatively regulated
by PTEN (Haluska et al., 2006; Tsugawa et al., 2002).
Increased PI3K activity has been found in cervical cancer-derived
tumors and cell lines (Bertelsen et al., 2006; Ma et al., 2000). This
event has been explained by the frequent ampliﬁcation of the region
3q24–29, where PI3K gene is located (PIK3CA), which is also linked
with an increase in Akt activated forms.
PI3K has also been related with activation of Mitogen-Associated
Protein Kinase (MAPKs), a family of proteins acting downstream in
mitogenic signaling (Chai et al., 2007; Wells et al., 2007). It has been
shown that an HPV16 variant E6, is able to enhance MAPKs signaling
in transfected cell lines, by means of its cooperation with the Notch
signaling pathway (Chakrabarti et al., 2004).
The aim of this study was to determine the role HPV18 E6 isolates
in the modulation of elements involved in the akt/PKB and MAPKs
signaling pathways. It was found that E6 variants differentially
modulate hDlg degradation, rebounding in levels of pPTEN and
activated PKB. HPV18 E6 variants were also able to upregulate
activated PI3K protein, strongly correlating with activated MAPKs
and cell proliferation. Results suggest that functional differences
within HPV18 variants may be also due to a differential ability to
activate cell-signaling pathways such as Akt/PKB and MAPKs, which
are directly involved in cell survival and proliferation.
Results
PTEN promoter methylation status in cervical cell lines
PTEN is a negative Akt/PKB pathway regulator. It has been
proposed that PTEN promoter activity may be regulated by epigenetic
mechanisms, because methylated PTEN has been detected in cervical
cancers (Cheung et al., 2004; Yang et al., 2006). A controversy exists
concerning such methylation. Zysman et al. (2002) reported that
certain primers could be detecting PTEN pseudogenes rather than
PTEN promoter. Therefore, in order to determine PTEN methylation
status in several cell lines, including cervical cancer, we used speciﬁc
primers that amplify PTEN promoter 5′ region, that discriminate
between PTEN and the pseudogene (Zysman et al., 2002). PTENpromoter methylation was not detected in MCF-7, Caski, HeLa, and
SiHa cell lines (Fig. 1a), while a proportion of methylated PTEN can be
observed in DNA from normal lymphocyte, increasing in DNA
methylated in vitro. Moreover, when the same cells were treated
with the DNA demethylating agent 5-Aza-2′-deoxycytidine, no
signiﬁcant changes in PTEN protein levels were found (data not
shown), discarding that methylation of other regions of PTEN
promoter could be regulating PTEN expression.
E6 modulates PTEN activity through interaction with hDlg
Other mechanisms, such as PTEN stabilization by hDlg, may be
involved in PTEN regulation, as occurs with other MAGUK family
members (Adey et al., 2000; Valiente et al., 2005). Because it is known
that E6 from HPV18 binds with high afﬁnity to hDlg, promoting its
degradation, we determined whether PTEN protein levels were
modiﬁed within the E6-variant context. No differences in PTEN
steady-state levels were observed in the presence of the distinct E6
variants (Fig. 1b). Nevertheless, different activated PTEN (pPTEN)
levels appeared within E6 transfected cells. The results clearly show
highly phosphorylated PTEN levels in cells lacking E6, whereas in cells
harboring AsAi- and E-E6 variants no visible pPTEN were observed
(Fig. 1b), while cells with the African E6 isolate presented a reduction
in pPTEN over basal levels. To verify if changes in pPTEN levels could
be due to differences in E6 expression, RT-PCR of E6 expression
analysis in transfected cells was performed. This analysis showed
similar transcriptional patterns as those previously reported for the
same variants (De la Cruz et al., 2005), where cells with E6 African
variant had a minor proportion of full-length E6 in relation to the
Fig. 4. (a) HPV18 E6 variants modulate differentially PI3K/Akt pathway. A) PKB levels
were compared within MCF-7 cells and those transfected with the HPV18 E6 isolates
(Af, E, and AsAi), or the pcDNA vector. Upper panel shows equivalent quantities of total
PKB protein within all cells analyzed by Western blot; Middle panel shows an increase
in pPKB (anti-p-Akt1/2/3(Ser 473) in E6 variants-harboring cells. Lower panel: anti-
actin as loading control. (b) Densitometric analysis of previously mentioned data. A
graph with mean±SD of three independent western blot experiments was drawn by
measuring the band intensities with NIH IMAGEN version 1.62. Results are expressed as
a percentage of increase above control cells (MCF-7 cells), in which the asterisk (⁎)
indicates signiﬁcant differences related to cells containing pcDNA vector (pb0.001
Student's t-test). (c) Western blot analysis of PI3K expression. Upper panel shows
homogeneous levels of PI3K total protein (anti- PI3-kinase p110) in tested cell lines.
Middle panel conﬁrms presence active PI3K (anti-p-PI3K p85α) in E- and AsAi-E6
containing cells.
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AsAi-E6 showed a higher proportion of full-length E6. Therefore,
when no pPTEN is found, a higher proportion of the full-length E6
transcript is present.
Because a direct interaction between E6 and PTEN has not been
demonstrated, to date, the previously cited observations could be the
result of differences in hDlg protein levels. Thus, we analyzed hDlg
protein steady-state levels in the presence of the different E6 variants.
Examination of E6 variant-transfected MCF-7 and C33A cell lines by
Western blot showed that control cells maintained higher hDlg levels,
than cells harboring the different E6 isolates, which suggests efﬁcient
hDlg-degradation promotion by E6 in both cell lines (Figs. 2a and b).
Nonetheless, reduction in hDlg levels is higher in AsAi and E-E6
harboring cells, than in cells with the African E6. hDlg levels directly
correlated with the proportion of activated PTEN. A decline in pPTEN
took place in Asian-Amerindian or European E6-containing MCF-7
cells (Fig. 1b) as well as in C33A cells containing the same E6 variants
(not shown), which could be a consequence of the lower hDlg levels
observed in these cell clones (Figs. 2a and b).
hDlg and PTEN interaction has already been demonstrated (Adey
et al., 2000), hence, we continued to verify whether this interaction
occurred in our system. Immunoprecipitation conﬁrmed in vivo PTEN
and hDlg interaction. A relative minor hDlg/PTEN amount was
observed in cells with AsAi-E6 (Fig. 3). This difference could be due
to the smaller amount of hDlg present in these cells, compared with
cells with E6–Af or without E6 (Figs. 1b and 2a).
E6 affects the Akt/PKB pathway through PTEN and PI3K modulation
Because PTEN is a negative regulator of the Akt/PKB pathway, we
proceeded to determine whether differences observed in PTEN
phosphorylation within E6 transfected cells could affect phosphory-
lated Akt/PKB levels. Analysis with the antibody recognizing p-Akt1/2/
3(Ser 473) isoforms, showed that while Akt/PKB cellular levels
remained constant, phosphorylated Akt/PKB (pPKB) was increased
in E6-harboring cells (Fig. 4a). Signiﬁcant differences were found in
AsAi and E-E6-harboring cells, as comparedwith control cells (Fig. 4b).
Lower pPKB levels were observed for the E6 African isolate,
concordant with a detectable amount of pPTEN also observed in
these cells.
Because the main positive Akt/PKB is PI3K regulator, we also
analyzed phosphorylated PI3K levels. As shown in Fig. 4c, PI3K steady-
state levels are maintained constant among transfected cells. Mean-
while, the PI3K phosphorylated form (pPI3K) is evidently increased in
Asian Amerindian and European E6-containing cells, in contrast with
cells with the empty pcDNA vector or the African E6, in which PI3K
activation appears not to occur.
PI3K participates in biological processes such as chemotaxis and
cellular proliferation (Graness et al., 1998). An association between
PI3K and MAPKs activation has also been reported (Chai et al., 2007;
Wells et al., 2007). Therefore, we analyzed whether differences in
pPI3K observed within E6 transfected cells, could vary MAPK down-Fig. 3. PTEN and hDlg interaction. Western blot analysis of cellular immunoprecipitates
from MCF-7 cells lines transfected with pcDNA vector alone, AsAi-, or Af-E6. Lysed
extracts were immunoprecipitated with anti-PTEN antibodies, anti-hDlg, antibodies, or
preimmunserum of sheep. Complexes were analyzed in Western blot with anti-hDlg or
anti-PTEN antibodies.stream targets. As depicted in Fig. 5a, we demonstrated that AsAi and
E-E6-transfected cells clearly presented an increase in p44 (pERK2)
and p42 (pERK-1) levels, which were related to pPI3K levels (Fig. 4c).
Finally, we investigated whether differential PI3K and MAPKs
activation could be related to proliferative rates. Signiﬁcant prolifera-
tion rate differences within E6 variants-transfected cells could be
observed (Fig. 5b). Proliferation rate (evaluated as number of cells in S
phase) was higher in cells harboring the different E6 variants than in
cells without E6 (pb0.05). Signiﬁcant differences were also observed
between cells with Af-E6 and cells with European or AsAi-E6 variants
(pb0.05) (Table1). Cells with the Af-E6 variant, presented the lowest
proliferation rate (25.1±5.89% of cells in S phase) within E6 containing
cells, while cells with AsAi- and E-E6 had higher proliferation rates
(83.8 9±12.3% and 69%±10.46% of cells in S phase, respectively), in
which elevated pPI3K and activated MAPKs levels were also found
(Figs. 4c and 5a).
HPV18-E6 activates akt/PKB through its effect on hDlg
To conﬁrm the contribution of E6 in the analyzed pathways, HPV18
E6 depletion was induced through small interfering RNA (siRNA) in
HPV18 genome-containing HeLa cervical cancer cell line. The effect of
E6 siRNAs on endogenous E6 mRNA expression was tested through a
semiquantitative Reverse transcription (RT)-Polymerase chain
Fig. 5. (a) HPV18 E6 variants differentially modulate the MAPKs pathway. Levels of activated MAPKs (pERK1 and pERK2) were determined in MCF7 E6 transfected cells in Western
blot. Lower panel shows immunoblots of the samemembraneswith anti-actin antibodies as protein-loading control. (b) A signiﬁcant increase in proliferation rate is induced by Asian
Amerindian and European E6. Representative histograms of DNA content show the effect on cell cycle distribution of E6 variant transfection (AsAi, E and Af), 48 h after cell cycle
arrest. Arrows indicate S phase of the cell cycle.
81A. Contreras-Paredes et al. / Virology 383 (2009) 78–85reaction (PCR) method. We found that 18E6 siRNA speciﬁcally
downregulated E6-encoding mRNA in HPV18-positive cells, while
the 16 E6 siRNA had no effect on E6 expression (Fig. 6a). 18E6 siRNA
decreased E6 mRNA levels in N70%. Next, we determined whether E6
depletion modiﬁed PKB and MAPKs pathways. The keratinocyte-
immortalized cell line HaCaTwas used as control inWestern blot assay
because it demonstrated high levels of the tested proteins. Fig. 6b
shows that while both hDlg and pPTEN aremaintained at low levels in
HeLa untreated cells, 18E6 siRNA transfected cells restore hDlg andTable 1
Cell Cycle analysis of MCF-7 E6 transfected cells
E6 content G0/G1 S G2/M
MCF-7 pcDNA 63.14 12.56±2.7 24.29
MCF-7 Af 53.54±10.2 25.1±5.89⁎ 21.36±2.8
MCF-7 E 23±3.1 69±10.46⁎, ⁎⁎ 7.9±0.5
MCF-7 AsAi 12.31±2.1 83.89±12.3⁎, ⁎⁎ 3.8±0.1
Percentage of cells in each phase of the cell cycle of MCF7 transfected with AsAi-, E-, or
Af-E6. Data are shown as means±SE of 3 experiments per transfection.
⁎ Pb0.05 (Student's t-test) as compared with MCF7-pcDNA.
⁎⁎ Pb0.05 (Student's t-test) as compared with MCF7-Af.activated PTEN proteins. In contrast, pPKB and ERKs (p42 and p44),
which are highly expressed in HeLa untreated cells, were reduced in
18E6 siRNA transfected cells. These data directly correlate with our
ﬁndings in E6 transfected cells. To evaluate the possible contribution
hDlg on the regulation of these pathways by E6, impact on hDlg
silencing onMCF7 cell linewas evaluated through siRNA. The outcome
of hDlg siRNA on endogenous hDlg expressionwas tested through the
analysis of protein levels. Fig. 6c shows that hDlg-siRNA transfection
clearly decreased hDlg levels inMCF-7 cells, with the consequence of a
reduction of pPTEN and an increment in pPKB. These data suggest that
the function of E6 on akt/PKB pathwaymodulationmay be due, al least
in part, to its ability to decrease the amount of hDlg.
Discussion
Akt/PKB comprises a cardinal node in diverse signaling cascades,
participating in normal cellular physiology, as well as in various
disease states including cancer. Different oncoproteins and tumor
suppressors intersect in the Akt/PKB pathway (Knobbe and Reifen-
berger, 2003). PTEN, a tumor suppressor gene, is a critical controller of
this pathway.
Fig. 6. Effect of HPV18 E6 siRNA in HeLa Cells. (a) mRNA E6 expression is downregulated
by HPV18 E6-siRNAs. HeLa cells were transfected with the indicated siRNA. After 2 days
of incubation, RNA was extracted and reverse-transcribed. cDNA samples were
subjected to PCR. As positive control, HeLa DNA was PCR ampliﬁed; negative control
is the PCR mixture without DNA. Intensities of E6 bands from E6 siRNA-treated cells
were normalized to the β-actin band. (b) Impact of E6 silencing on PKB and MAPKs
signaling pathways. Cell lysates of HPV18 E6-siRNA treated and untreated cells were
separated by SDS-PAGE and transferred onto nitrocellulose membrane. Western blots
demonstrate that E6 silencing augments hDlg and phosphorylated PTEN in HeLa cells,
while pPKB and pMAPKs levels are reduced. (c) Impact of hDlg silencing on PKB
signaling pathway in MCF-7 cells. Western blots show that hDlg-siRNA transfection
unambiguously reduces hDlg protein levels decreasing pPTEN; contrarily, pPKB is
increased. Data is compared with MCF-7 cells transfected with AsAi-E6.
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in some cases a downregulation has been observed in PTEN protein
(Cheung et al., 2004; Tashiro et al.,1997). Some authors have explained
this as a possible consequence of PTEN promoter methylation (Cheung
et al., 2004). Itwas previously demonstrated that certain PTENdirected
primers were also capable of amplifying pseudogenes (Zysman et al.,
2002), with the possible consequence of overestimation of PTEN
methylation. In this study, through the use of PTEN speciﬁc primers
that amplify a region speciﬁc to PTENpromoter that is not homologous
to the pseudogene, the absence of PTEN methylation in HPV genome-
containing cervical cell lines was demonstrated. Furthermore, no
differences in PTEN protein expression were found between cells
treated and untreated with the DNA demethylating agent 5-Aza-2′-
deoxycytidine, discarding regulation by methylation of other regions
of PTENpromoter. This suggests that promotermethylationmaybe not
a main PTEN-regulating mechanism in cervical cancer.
It has been proposed that high risk HPV E6 and E7 proteins
contribute to Akt/PKB pathway activation, although a clear mechan-
ism has not been elucidated (Pim et al., 2005). In this work, we
proposed that one way in which E6 could regulate this pathway is
through modulating PTEN, by means of its interaction with hDlg.
It is known that hDlg can bind PTEN (Adey et al., 2000); therefore,
as a MAGUK family member hDlg could also be acting as a scaffold
protein, stabilizing and promoting PTEN activation. In this study wefound a clear inﬂuence of E6 on activated PTEN levels, correlating with
the proportion of hDlg protein observed in HPV18 E6 transfected cells.
Higher amounts of hDlg and activated PTEN were observed in African
E6 variant-harboring cells, comparedwith cells with AsAi or E-E6. This
ﬁnding may be attributed to a lower amount of functional E6 protein
present in cells with Af-E6. De la Cruz et al. (2005) reported that
differences in E6 levels could be due to the presence of distinct
proportions of splicing products; describing a higher proportion of
E6⁎I splicing product, compared with full-length E6 transcript, in
African E6-transfected cells. Similar E6 transcriptional patterns were
conﬁrmed in this work. It is noteworthy that E6⁎I spliced product
would generate a shortened protein without the original PDZ binding
domains, necessary for hDlg binding. Therefore the data obtained,
regarding differences observed within variants particularly E6–Af,
may be explained by a diminished proportion of full-length E6 protein
or else by different interactions of Af-E6 protein,
A role of HPV18 E7 protein in Akt/PKB pathway activation has been
proposed and is explained through a direct PP2A phosphatase inhibition
(Pim et al., 2005). Nevertheless, a link between E6 and this pathway has
not been described to date. This work shows that E6 effect on PTEN
activation can reﬂect a direct outcome on Akt/PKB. Results show that
while E6 variants did not affect total PKB levels, an increment in its
phosphorylated form was observed in E6-harboring cells, compared to
cells without E6. Moreover, slight differences are appreciated within
variants, in which AsAi-E6 containing cells appear to present a higher
amount of pPKB, followed by cells with the E isolate, with a lesser
amount in Af-E6 containing cells. These ﬁndings correlate with the
distinct proportions observed of phosphorylated PTEN. Thus, it is
possible that E6 effect on Akt/PKB is due in part to its effect on hDlg.
PI3K reverses PTEN process, generating inositol phospholipids that
trigger Akt/PKB phosphorylation. In cervical cancer, enhanced PI3K
activation has been reported (Bertelsen et al., 2006). Nair et al. (2003)
recognized that PI3Kmay possess a key role in transformation of HPV-
infected cells, proposing that HPV16 E6 and E7 could be cooperating
with PI3K for cell transformation, through the Notch-1 pathway
activation. However, there are no previous evidences relating a
straight E6 effect on PI3K activity. The results obtained in this work
show that cells with E and AsAi-E6 variants presented a substantial
increase in pPI3K. No effect on this enzyme was observed in cells with
Af-E6, which may be the result of a minimal amount of E6 protein, or
that amino acid variations contained in such an E6-variant, render it
deﬁcient for such activation. Therefore, we suggest that E6 is not only
capable of modulating Akt/PKB through PTEN regulation, but that it
may also exert an inﬂuence through PI3K activation. However, it is not
clear which E6 mechanism could be acting on PI3K regulation.
With the large increase in pPI3K, together with the absence of
activated PTEN occurring in cells with E and AsAi-E6, a higher
proportion of activated PKB than the one observed in our systemwas
expected. The answer to this query may be found in that the
proportion of pPKB may be a result not only of activating kinases
(PDK1, PDK2), but also of inactivating phosphatases (PP2A, STAT3)
(Pim et al., 2005; Sun and Steinberg, 2002) that may be modulating
the ﬁnal proportion of activated pPKB.
It is widely known that a main target of PI3K is PKB. Nevertheless,
PI3K may also activate other pathways independently. ERKs are the
most importantly characterized MAPKs proteins in cell proliferation
(Jorda et al., 2007). It has been shown that PI3K pathway disturbances
block MAPK activation, suggesting a role for PI3K in MAPK function
(Chai et al., 2007; Kranenburg et al., 1997; Roymans and Slegers, 2001;
Wennstrom and Downward, 1999).
A link between HPV16 E6 and an increase in the activity of MAP
kinases, speciﬁcally ERK1 and ERK2, has been previously established,
with a differential effect for E6 variants (Chakrabarti et al., 2004). Such
an E6 outcome was explained by means a Ras independent effect,
involving Rap-1. Data presented here support an effect of HPV18 E6 on
MAPKs that in contrast, may be due to PI3K modulation. In this work,
83A. Contreras-Paredes et al. / Virology 383 (2009) 78–85we speciﬁcally observed pERK1(p42) and pERK2 (p44) upregulation in
the presence of AsAi-E6 and E-E6, possibly owing to PI3K activation.
Notwithstanding this, the participation of another pathway such as
that proposed by Chakarabarti et al., (2004), is not discarded.
Even at the lowest rate, cells with Af-E6 showed an increment in
proliferation above control cells. In these cells, no differences in
pMAPKs or pPI3K levels were observed; therefore, while MAPKs may
be participating in the observed increase in proliferation, other
proliferative pathways may be affected by E6.
It is known that all HPV types are able to induce hyperproliferative
lesions. This effect has been attributed to E6 and E7 proteins.
Evidences that support a main role of E6 in cell proliferation highlights
the effect of this protein on p53 degradation. Nevertheless, E6 is able
to bind to a variety of proteins critical in cell cycle regulation,
independently of p53, causing a shortening in G1 phase. For instance,
it has been reported that E6 is able to release E2F1 due to the
induction of pRB phosphorylation, inducing an increase in DNA
synthesis (Malanchi et al., 2004). On the other hand, hDlg can form a
complex with the adenomatous polyposis coli (APC) suppressor
protein that stops cells in G1 (Ishidate et al., 2000). This checkpoint
can be eliminated when E6 targets hDlg for its degradation. It is now
shown that E6 also promotes a downregulation of PTEN activity,
whose role is critical in controlling important proliferative pathways.
In addition, we demonstrate that some HPV18 E6 variants can
upregulate PI3K activity, which correlates with differences found in
activated MAP kinases. Thus, the observed proliferative rates may be
the result of several converging E6-altered pathways.
Correlations found in this work were conﬁrmed through E6
silencing in HeLa cells. 18E6-siRNA treated HeLa cells, containing
HPV18 genome, increased phosphorylated hDlg and pPTEN levels, at
the same time as pPKB and activated MAPKs decreased. This result
conﬁrms the speciﬁc participation of E6 inmodulating such pathways.
Furthermore, siRNA-hDlg silencing in MCF-7 cell line resulted also in a
decline of pPTEN and an increase pPKB, so is highly suggestive that E6
is modulating such pathways in part by its interaction with hDlg
Differential regulation ofmembers involved in Akt/PKB andMAPKs
pathways due to HPV18E6 isolates, was found in this work. We now
propose that hDlg interaction with E6 plays an important role in
proliferative and survival pathway modulation. Future efforts should
be carried out in order to establish variant oncoprotein dynamics with
cellular proteins involved in other biological effects, including
apoptosis. These data add to evidences disclosing that HPV intra-
type variations can rebound in viral biological behavior.
Materials and methods
Cell cultures and transfection
C33A, and MCF-7 cell lines were grown in Dulbecco's modiﬁed
Eagle's medium (DMEM-F12, GIBCO-BRL) supplemented with 8% fetal
bovine serum (FBS). Stable transfections were carried out in MCF-7
and C33A cell lines with 4 μg DNA from either vector alone (pcDNA3.1)
or vectors harboring E6 variant genes from African (Af), European (E)
and Asian Amerindian (AsAi) HPV18 isolates (De la Cruz et al., 2005).
For stable selection, cells were treated 24 h after transfection with
0.8 mg ml−1 of G418 in DMEM-F12 for 3 weeks to initiate analysis and
resistant clones were cultured permanently with G418. E6 integrity
and expression was analyzed in stable transfected cells by PCR
ampliﬁcation, sequencing, and RT-PCR.
Methylation-speciﬁc polymerase chain reaction (MSP)
The methylation status of PTEN promoter was determined in MCF-
7 Caski, HeLa and SiHa cell lines, by DNA bisulﬁte modiﬁcation
followed by methylation-speciﬁc PCR, as previously described by
Herman et al. (1996). Brieﬂy, 1 μg of DNA in 100 μl of each sample wasdenatured with freshly prepared NaOH at a ﬁnal concentration of
0.2 M for 20 min at 42 °C. Freshly prepared 10 mM hydroquinone
(Sigma) and 520 μl of 3 mM sodium bisulﬁte at pH=5 (Sigma), were
both added and mixed. The sample was incubated at 55 °C for 16 h.
Modiﬁed DNA was puriﬁed using Wizard DNA puriﬁcation resin
according to manufacturer (Promega) instructions and eluted in 50 μl
of water. Modiﬁcation was completed by NaOH treatment (ﬁnal
concentration 0.3 mM) for 10 min at room temperature, followed by
ethanol precipitation. DNA was resuspended in water and used
immediately or stored at −20 °C.
Bisulﬁte modiﬁed DNA (100 ng) was PCR-ampliﬁed with the
following gene-speciﬁc primers (Zysman et al., 2002): Methylated
PTEN promoter: 5′-TTTTTTCGGTTTTTCGAGGC-3′ (sense), 5′-
CAATCGCGTCCCAACGCCG-3′ (antisense); unmethylated PTEN Promo-
ter: 5′TTTTGAGGTGTTTGGGTTTTTGGT3′ (sense), 5′CACAATCACATCC-
CAACACCA 3′ (antisense).
The PCR ampliﬁcation mixture contained 1× PCR buffer, dNTPs at
1.28 mmol each: primers (10 pmol Invitrogen), TaqGold polymerase
(1 U; Applied Biosystems), and bisulﬁte-modiﬁed DNA (100 ng) or
unmodiﬁed DNA (100 ng) in a ﬁnal volume of 20 μl. DNAwas ampliﬁed
with the following steps for both ampliﬁcation reactions: an initial
10 min denaturation at 94 °C, followed by 35 cycles of 94 °C for 30 s,
59 °C for 30 s, and 72 °C for 35 s, and a ﬁnal elongation step of 7 min at
72 °C. Products were visualized in 2% agarose gel under Ultraviolet
(UV) light. A gene was expected to be methylated whenever a band
was present after ampliﬁcation with the methylated set of primers, or
with both methylated and unmethylated set of primers. Contrariwise,
a gene was deemed unmethylated when a band was present after
ampliﬁcationwith the unmethylated set in the absence of a band with
the methylated set.
Inﬂuence of methylation in PTEN expression was analyzed by cell
treatment with 0.75 μM of the methylation inhibitor 5-Aza-2′-
deoxycytidine for 48 h. Treated and untreated cell lysates were
analyzed by western blot with speciﬁc anti-PTEN antibodies.
Western blot analysis
Total cellular proteins were extracted from transfected cells
harvested from 75 cm2 ﬂask. Cell proteins from C33A and MCF-7
cell lines were extracted with 300 μl of RIPA lysis buffer [100 mM tris
pH 8, 50 mM NaCl, 0.5% Nonidet P-40, 1% aprotinin, and 1 mM PMSF
(Sigma)]. Proteins were boiled for 5 min in sample buffer [125 mM
Tris/HCl pH 6.8, 1% SDS, 2%-mercaptoethanol and 0.01% bromophenol
blue], and then 40 μg of cell lysates were loaded onto SDS-PAGE gels
(8–12%). After electrophoresis, proteins were transferred onto
Hybond-C nitrocellulose membrane (Amersham Biosciences) in a
wet chamber for 1 h at 100 V. Membranes were then blocked with 1×
TBS (1% skimmed milk and 0.1% Tween 20), followed by incubation
with the respective primary antibody [hDlg, PTEN, pPTEN, PI3K, pPI3K,
Akt/PKB, pAkt, Actin, ERK1/2 and pERKs (Santa Cruz Biotechnology,CA.
USA)]. Membranes were incubated with Horseradish peroxidase-
conjugated secondary antibody and the levels of the corresponding
proteins were visualized utilizing the ECL system (Amersham,
Biosciences). Western blots were performed three times each to
assure result reproducibility. Next, denstitometric analysis of Western
blots was carried out with NIH IMAGEN version 1.62. Means±standard
deviation (SD) are shown.
Immunoprecipitation
MCF-7 cells transfected with E6 expression vector or the vector
alone, were washed twice with ice-cold PBS and lysed with RIPA cold
buffer (containing protease inhibitors). Afterwards, the supernatant
was precleaned with anti-mouse IgG/agarose for 2 h (Santa Cruz
Biotechnology, CA. USA). Anti-PTEN antibodies, anti-hDlg antibodies
or anti-sheep control antibodies were incubated for 2 h at 4 °C with
84 A. Contreras-Paredes et al. / Virology 383 (2009) 78–85Protein G-Agarose beds (Santa Cruz Biotechnology, CA. USA). 100 μl of
cell lysates (500 μg/ml) were incubated with, the antibody mixtures
overnight at 4 °C. The immunoprecipitates were washed twice with
lysis buffer, resuspended in Laemmli sample buffer, and submitted to
Western blot with anti-hDlg or PTEN antibodies.
Flow cytometer
For cell cycle arrest, cells were grown in minimum essential
medium (DMEM) plus fetal calf serum at a ﬁnal concentration of 2%
(400×103 cells/well in a 6-well plate) for 12 h. After adding fresh
medium with 10% SBF, the analysis was performed 48 h later. Cells
were harvested by trypsinization and ﬁxed in 70% ethanol overnight.
Cells were then stained with 10 mg/ml propidium iodide (PI) for 1 h
and analyzed for DNA content on a FACScan ﬂow cytometer (Calibur
Beckton Dickinson). Debris and aggregates were gated out during data
acquisition, and 10,000 gated events were collected for each sample.
Cell cycle analyses were performed for duplicate samples employing
Cell QUEST software (Tree Star, Inc.). Results are expressed in
percentage of cells in S-phase.
E6 and hDlg SiRNA synthesis
The following desalted oligonucleotide were purchased from
Invitrogen: HPV-18 E6 antisense 5′-GAG GTA TTT GAA TTT GCA TTT
CCT GTC TC-3′; sense 5′- ATG CAAATT CAAATACCT CTT CCT GTC TC-3′
as reported by Yamato et al. (2006); and HPV-16 E6 antisense 5′-GAA
TGT GTG TAC TGC AAG CTT CCT GTC TC-3′; sense 5′-GCT TGC AGT ACA
CAC ATT CTT CCT GTC TC-3′ (Jeong et al., 2007). hDlg antisense 5′ -
AAA TTC TCA ATC TCT GATAAG CCT GTC TC- 3′; sense 5′- AAC TTA TCA
GAG ATT GAG AAT CCT GTC TC-3′.(Laprise et al., 2004). Oligonucleo-
tide-directed production of small RNA transcripts with T7 RNA
polymerase has been previously described (Donzé and Picard, 2002).
For each transcription reaction,10mmol template oligonucleotidewas
hybridized to the T7 promoter primer in DNA hybridization buffer, the
mixture was incubated at 70 °C for 5 min. The template was ﬁlled in
with Exo-Klenow (Ambion Inc, The RNA Company) in a 20 μl reaction
mixture and incubated at 37 °C for 30 min. For each siRNA template,
two independent reactions were carried out to synthesize sense and
antisense RNA strands. Independently synthesized sense and anti-
sense transcription reactions were mixed together in a single tube and
followed by incubation at 37 °C overnight. The resulting dsRNA carried
5′ overhanging leader sequences that required removal prior to
transfection, with a single-strand speciﬁc ribonuclease.
SiRNA transfections
1×106 HeLa cells were transfected with 100 nM of each siRNA
(HPV-18 or HPV16-E6). Transfections were performed in 3 cm
diameter dishes with Lipofectamine Plus (Gibco-BRL) according to
manufacturer instructions. After 48 h of transfection, cells were
processed to obtain RNA or protein. E6 transcript Integrity was tested
by RT-PCR ampliﬁcation. The same protocol was followed for hDlg
siRNA transfection in MCF7 cell line save for using 150 nM of the
respective siRNA.
RNA extraction and expression analysis
Total RNA was obtained from transfected cells by using TRIzol
(Invitrogen Life Technologies) according to manufacturer's instruc-
tions. Samples were treated with 1 U DNase I (Gibco-BRL). The
amount of RNA was determined by UV spectrophotometry and
quality was assessed in 2% agarose gels. For cDNA preparation, 2 μg
total RNA was reverse-transcribed with random hexamers utilizing
the Gene-Amp RNA PCR Kit system for RT-PCR (Applied Biosystems,
ROCHE).Statistical analysis
Data showing the effects of E6 variation of HPV18 in cell
proliferationwere expressed as means±SD, and signiﬁcant differences
were determined using Student's t-test.
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